Antidepressants and Sexual Side Effects: The Numbers Nobody Quotes

This is the side effect men are least likely to raise and doctors are least likely to ask about, which is why the reported rate depends almost entirely on the method used to measure it.

Why the numbers vary so wildly

You will see this side effect quoted at anywhere from a few percent to over 80%. Both ends are real measurements, and the gap between them is a measurement artefact rather than a disagreement about biology.

A study using structured assessment found sexual dysfunction in 84.5% of men and 88.7% of women taking antidepressants, at some level of severity. A careful review of the broader literature put a realistic estimate at somewhere between 30 and 50%.

The difference is how you ask. In the same study, only 42.5% of men volunteered the information without being prompted. Fewer than half. The authors’ conclusion is blunt: spontaneous reporting substantially underestimates prevalence, and structured questioning should be used instead.

The practical consequence for you is simple. If nobody asked, the absence of a note in your record is not evidence that you did not have it.

What it actually does

In men, the effects cluster around desire and orgasm. Specifically:

• Reduced libido — the most common complaint, and the one most easily mistaken for depression itself
• Delayed or absent orgasm — the most characteristic effect of serotonergic drugs
• Reduced intensity of orgasm, sometimes described as muted rather than absent
• Erectile difficulty, less consistently than the above
• Reduced genital sensation in some men

The delayed-orgasm effect is so reliable that it is used deliberately: off-label SSRIs are a first-line treatment for premature ejaculation, on a strong recommendation from the American Urological Association. The same mechanism that makes them useful there is what causes the problem here.

One genuinely difficult diagnostic point: depression itself reduces libido. A man whose desire has fallen while starting an antidepressant cannot easily tell whether the drug caused it or the illness did. The usual discriminator is timing — dysfunction that appears or worsens after starting or increasing a dose, particularly while mood is improving, points at the drug.

Why it happens

Serotonin inhibits the ejaculatory reflex, and increasing serotonergic transmission is the mechanism by which SSRIs treat depression. The sexual effect is not an accident of the molecule; it is a consequence of the intended action.

That also explains the pattern across drug classes. Drugs that raise serotonin — SSRIs and SNRIs — carry the highest rates. Bupropion, which works on dopamine and noradrenaline rather than serotonin, carries substantially lower rates, and in the study above women on bupropion had significantly less dysfunction than those on SSRIs, SNRIs or vortioxetine.

An honest qualification about drug-by-drug rankings. It is widely repeated that paroxetine is the worst offender and that certain agents are safe. The individual trial numbers vary enormously between studies — citalopram has been reported at 73% in one and 40% in another — and one review found the evidence insufficient to support firm claims about differences between agents. The class-level difference between serotonergic drugs and bupropion is well established. The fine-grained league table is less so.

What has evidence behind it

Three strategies have randomised controlled trial support. That is a short list, and it is worth knowing which three.

The single most important thing on this page: do not stop the antidepressant yourself. Abrupt discontinuation of serotonergic drugs produces a well-recognised withdrawal syndrome, and relapse of the depression is a considerably worse outcome than the side effect you are trying to escape. Every option above is a conversation with a prescriber, and all of them are routine requests.

The persistent form

Post-SSRI sexual dysfunction, or PSSD, is defined as treatment-emergent sexual dysfunction that persists for a month or more after the drug is stopped. The European Medicines Agency formally recognised it in June 2019.

It deserves careful handling, because it is simultaneously real and rare, and both halves get lost depending on who is describing it.

It is real. A regulator does not add a warning without cause, and the symptom pattern is distinctive: reduced libido, genital anaesthesia — a loss of sensation rather than just of desire — and pleasureless orgasm. Cases lasting six years and more after discontinuation are documented.

It is rare. One estimate put the incidence at about 0.46%, roughly one in 216 people treated with serotonergic antidepressants. The authors are candid that this is likely an underestimate, since it was derived from prescription data rather than direct symptom reporting.

There is no established treatment. The literature’s own summary is that the only established approach is prevention, and the practical advice offered is to raise it promptly — particularly genital numbness — rather than waiting to see whether it resolves.

None of that is an argument against taking antidepressants. Untreated depression is dangerous, and in men it is dangerous in a specific and well-documented way. It is an argument for knowing what to report and when.

How to raise it

Given that fewer than half of men bring this up on their own, a small amount of scripting genuinely helps.

Say what changed and when: “since starting this, my sex drive has gone” or “I can’t finish.” Both are ordinary clinical sentences and a prescriber has heard them many times that week.

Say whether the depression is improving, because that determines the strategy. A drug that is working with an intolerable side effect is a different problem from one that is not working at all.

Mention genital numbness specifically if you have it, because that is the symptom associated with the persistent form and the one worth acting on early.

And if the underlying question is whether the problem is the drug, the depression, or something else entirely, the physical-versus-psychological distinction is a useful place to start.

This article is for information only and is not medical advice. It cannot account for your individual circumstances. Talk to a doctor about your own situation, particularly before starting or stopping any prescription medication. If you are struggling, that is worth raising with a clinician rather than managing alone.